News archive

JPIAMR welcome the Independent AMR Review Final report “Tackling Drug-Resistant Infections Globally: Final Report and Recommendations” that highlights the importance to tackle Antimicrobial resistance (AMR) on a global level. –  As resistant bacteria know no national borders, we need to work at an international scale to tackle antimicrobial resistance, which is exactly what we do […]

The 10 Joint Programming Initiatives (JPIS) has presented the last GPC meeting a Joint Statement of the 10 JPIs Chairs. The Statement follows the Lund Statement of the JPIs last December and aims to react to the recent Evaluation Report regarding the progress of the different JPIs. The statement highlights: • JPIs as one of […]

Please note the specific Call Topic: Addressing the clinical burden of Clostridium difficile infection (CDI): evaluation of the burden, current practices and set up of a European research platform (part of the IMI New Drugs for Bad Bugs (ND4BB) programme) Deadline for submitting short proposals under Call 9: Tuesday 26 July 2016.  Find out more […]

The symposium is organized jointly by the Medicinal Chemistry Section of the Swedish Pharmaceutical Society and ENABLE, one of the projects in the Innovative Medicines Initiative ND4BB, to showcase the future and opportunities for antibiotic drug discovery in a stimulating environment. It is also designed to provide plenty of opportunities to meet other delegates, renew […]

The JPIAMR, in partnership with 8 European countries (Belgium, France, Germany, Netherlands, Norway, Spain, Sweden and the UK), and Canada, is launching a fourth joint call for working group proposals.  The call sets out to assemble motivated groups of leading experts and establish Working Groups in order to enhance resource alignment and maximise existing and […]

IMI2 Prelaunch Flyer The Innovative Medicines Initiative (IMI) will soon launch its 9th Call for proposals under IMI 2. The Call will include the topic: Addressing the clinical burden of Clostridium difficile infection (CDI): evaluation of the burden, current practices and set up of a European research platform (part of the IMI New Drugs for […]

The Conference will review what needs to be done to achieve a more prudent and appropriate use of antibiotics in the European Union (EU), with an emphasis on human use. It will bring together experts and policy makers on antimicrobial resistance. Read more

The development of new antibiotics is a major aspect strongly associated to AMR. In a two days symposium international experts communicate state-of-the-art science from the definition of the problem. Read more    

The Bill and Melinda Gates foundation has launched a call for ‘Novel Approaches to Characterizing and Tracking the Global Burden of Antimicrobial Resistance’. The goal is to identify approaches that provide more robust and reliable evidence regarding the global scale, impact, and/or transmission dynamics of AMR, specifically as applicable to low- and middle-income settings. The call also […]

The European Parliament could play a crucial role in shaping a European prudent use of antibiotics policy and JPIAMR can provide evidence and data to support such a policy. JPIAMR should also provide best practice guidelines. This was the main message from a meeting JPIAMR organised on 16 February 2016 with European Parliamentarians to discuss […]